The American Journal of Medicine
Volume 121, Issue 5 , Pages 426-432 , May 2008

Is Serum Cystatin-C a Reliable Marker for Metabolic Syndrome?

  • Aude Servais, MD

      Affiliations

    • Department of Nephrology, Pitié Salpêtrière Hospital, Paris, France
    • Corresponding Author InformationRequests for reprints should be addressed to Aude Servais, MD, Service de Néphrologie, Hôpital Necker, 149 rue de Sèvres, Paris 75015, France.
    • ,
  • Philippe Giral, MD, PhD

      Affiliations

    • Cardiovascular Prevention Center, Pitié Salpêtrière Hospital, Paris, France
    • ,
  • Maguy Bernard, MD, PhD

      Affiliations

    • Department of Biochemistry, Pitié Salpêtrière Hospital, Paris, France.
    • ,
  • Eric Bruckert, MD, PhD

      Affiliations

    • Cardiovascular Prevention Center, Pitié Salpêtrière Hospital, Paris, France
    • ,
  • Gilbert Deray, MD, PhD

      Affiliations

    • Department of Nephrology, Pitié Salpêtrière Hospital, Paris, France
    • ,
  • Corinne Isnard Bagnis, MD, PhD

      Affiliations

    • Department of Nephrology, Pitié Salpêtrière Hospital, Paris, France

References 

  1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752
  2. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med. 2006;19(5 Suppl 1):S3–S9
  3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–689
  4. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–2716
  5. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167–174
  6. Chen J, Gu D, Chen CS, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22(4):1100–1106
  7. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006;17(4 Suppl 2):S81–S85
  8. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221–226
  9. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37(1):79–83
  10. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29–34
  11. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem. 2000;37(Pt 1):49–59
  12. Mangge H, Liebmann P, Tanil H, et al. Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis. Clin Chim Acta. 2000;300(1-2):195–202
  13. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049–2060
  14. Risch L, Drexel H, Huber AR. Cystatin C and the risk of death. N Engl J Med. 2005;353(8):842–844author reply 842-844
  15. Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006;17(1):254–261
  16. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130(6):461–470
  17. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59(1):1–8
  18. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112(5):666–673
  19. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066–1076
  20. Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45(2):268–271
  21. Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16(12):3728–3735
  22. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142(7):497–505
  23. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(2):173–179
  24. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51(2):321–327
  25. Risch L, Blumberg A, Huber A. Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants using serum cystatin C. Nephrol Dial Transplant. 1999;14(8):1991–1996
  26. Meier P, Froidevaux C, Dayer E, Blanc E. Cystatin C concentration and glomerular filtration rate. Lancet. 2001;357(9256):634–635
  27. Herget-Rosenthal S, Trabold S, Pietruck F, et al. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol. 2000;20(2):97–102
  28. Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53:480–488
  29. Shlipak MG, Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006;17(1):254–261
  30. Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans (The Inter-Tribal Heart Project). J Am Soc Nephrol. 2002;13(6):1626–1634
  31. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14(2):469–477
  32. Tanaka H, Shiohira Y, Uezu Y, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69(2):369–374
  33. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16(7):2134–2140
  34. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293–301
  35. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51(6):1908–1919
  36. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260–269
  37. Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65(5):1870–1876
  38. Fliser D, Kielstein JT, Menne J. Insulin resistance and renal disease. Contrib Nephrol. 2006;151:203–211
  39. Eidemak I, Feldt-Rasmussen B, Kanstrup IL, et al. Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia. 1995;38(5):565–572
  40. Kobayashi S, Maesato K, Moriya H, et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45(2):275–280
  41. Sechi LA, Catena C, Zingaro L, et al. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes. 2002;51(4):1226–1232

PII: S0002-9343(08)00150-2

doi: 10.1016/j.amjmed.2008.01.040

The American Journal of Medicine
Volume 121, Issue 5 , Pages 426-432 , May 2008

Article Tools

* Image Usage & Resolution